<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958880</url>
  </required_header>
  <id_info>
    <org_study_id>KS09-088</org_study_id>
    <secondary_id>KS09-088</secondary_id>
    <nct_id>NCT00958880</nct_id>
  </id_info>
  <brief_title>Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety</brief_title>
  <official_title>Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Methodist University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Methodist University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the utility of Yohimbine hydrochloride for
      facilitating fear extinction in a sample of patients with social phobia who will be treated
      with CBT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to determine the relative efficacy of exposure-based CBT for social phobia
      when conducted with adjunctive acute (prior to four of five sessions) administration of
      either Yohimbine hydrochloride (10.8 mg) or placebo during core exposure sessions. Based on
      the available evidence, the investigators hypothesize that acute treatment with Yohimbine
      hydrochloride prior to exposure-based CBT would facilitate the extinction of fear that occurs
      with this treatment and would enhance treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Liebowitz Social Anxiety Scale (LSAS)</measure>
    <time_frame>LSAS means at 1 month follow-up</time_frame>
    <description>The Liebowitz Social Anxiety Scale (LSAS) is a self-report measure of social anxiety symptom severity. Scores range from 0 to 144, with higher scores indicating more social anxiety symptoms severity (i.e., a worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social Phobic Disorders Severity and Change Form</measure>
    <time_frame>CGI change scores from baseline to 1 month follow-up</time_frame>
    <description>Social Phobic Disorders Severity and Change (SPDSC) Form is a version of the Clinical Global Improvement-Severity scale adapted specifically for clinician ratings of social anxiety disorder symptom severity. The scale ranges from 0 to 5, with higher scores indicating more social anxiety symptoms severity (i.e., worse outcomes). We examined the change in SPDSC scores from baseline to a 1 month follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yohimbine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group Cognitive Behavioral Therapy</intervention_name>
    <description>5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations
One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_label>Yohimbine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yohimbine Hydrochloride</intervention_name>
    <description>Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.</description>
    <arm_group_label>Yohimbine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients between 18 and 65 years of age with a primary psychiatric
             diagnosis (designated by the patient as the most important source of current distress)
             of non-generalized social anxiety disorder (SAD) or Generalized Social Anxiety
             Disorder (GSAD) with a significant fear of public speaking as defined by DSM-IV
             criteria.

          2. Severity of the social phobia of at least 3 on the CGI scale rated for the severity of
             public speaking anxiety

          3. Willingness and ability to comply with the requirements of the study protocol.

        Exclusion Criteria:

          1. A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders
             or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic
             brain syndrome, mental retardation or other cognitive dysfunction that could interfere
             with capacity to engage in therapy; a history of substance (amphetamines,
             benzodiazepines, barbiturates, cocaine metabolites, marijuana, narcotics, and sedative
             hypnotics) abuse or dependence or alcohol abuse or dependence (other than nicotine) in
             the last 6 months or otherwise unable to commit to refraining from alcohol use during
             the acute period of study participation.

          2. Patients with posttraumatic stress disorder within the past 6 months are excluded.
             Entry of patients with other mood or anxiety disorders will be permitted if the social
             anxiety disorder is judged to be the predominant disorder, in order to increase
             accrual of a clinically relevant sample. Patients with significant suicidal ideation
             (BDI item 9 score &gt; 1) or who have enacted suicidal behaviors within 6 months prior to
             intake will be excluded from study participation and referred for appropriate clinical
             intervention.

          3. Given that Yohimbine hydrochloride is frequently used as an adjunctive medication in
             order to decrease side effects commonly resulting from antidepressant use (Pollack &amp;
             Smoller, 1996), antidepressant and anxiolytic medications are acceptable if they are
             stabilized for at least 8 weeks prior to the baseline assessments. However,
             individuals taking monoamine oxidase inhibitors or tricyclic antidepressants will be
             excluded from the study unless they are able and willing to discontinue these
             medications prior to baseline screening.

          4. Individuals taking antihistamines or strattera (atomoxetine) will be excluded from the
             study unless they are able and willing to discontinue these medications prior to
             baseline screening

          5. Evidence through interview or physical exam of significant general medical condition
             (e.g renal, endocrine, hepatic, respiratory, cardiovascular, hematologic, immunologic
             or cerebrovascular disease, or malignancy) that may interfere with the interpretation
             of safety and efficacy evaluations in the opinion of the prescribing physician.

          6. Resting blood pressure â‰¥ 160 systolic and/or 100 diastolic. Individuals currently
             being treated for high blood pressure and meeting these criteria are eligible.

          7. Significant personality dysfunction likely to interfere with study participation.

          8. Patients with a current or past history of seizures

          9. Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier
             devices, condoms and foam, or implanted progesterone rods stabilized for at least 3
             months). A urine pregnancy test will be performed on all female subjects of
             child-bearing potential at the screening visit.

         10. Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing
             psychotherapy of any duration directed specifically toward treatment of the SAD is
             excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on
             exploring specific, dynamic causes of the phobic symptomatology and provides
             management skills. General supportive therapy initiated &gt; 3 months prior is
             acceptable.

         11. Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's
             report of receiving specific and regular exposure assignments as part of a previous
             treatment) will exclude participants from the study.

         12. Patients with a history of head trauma causing loss of consciousness, seizure or
             ongoing cognitive impairment.

         13. Patients unable to understand study procedures and participate in the informed consent
             process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasper Smits, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Methodist University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael W Otto, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Methodist University</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bu.edu/anxiety</url>
    <description>BU Center for Anxiety and Related Disorders</description>
  </link>
  <reference>
    <citation>Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. 2009 Apr;23(3):350-6. doi: 10.1016/j.janxdis.2009.01.001. Epub 2009 Jan 15.</citation>
    <PMID>19223151</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>May 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2013</results_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Methodist University</investigator_affiliation>
    <investigator_full_name>Jasper Smits, Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened for eligibility criteria using an online screen. Potentially eligible participants were invited to the laboratory for a psychiatric interview. Eligible participants were enrolled in the Dallas area from 2009 to 2012.</recruitment_details>
      <pre_assignment_details>Participants were not enrolled if they did not meet the study inclusion criteria at a psychiatric screening or medical evaluation designed to rule out contraindicated psychiatric or medical conditions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Participants received placebo (sugar pill) augmented Group Cognitive Behavioral Therapy. The pills were administered 1 hour prior to sessions 2-5 of a 5-session group exposure-based CBT protocol.</description>
        </group>
        <group group_id="P2">
          <title>Yohimbine Hydrochloride</title>
          <description>Participants received Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy. Participants received Yohimbine HCL augmented Group Cognitive Behavioral Therapy. The 10.8 mg pills were administered 1 hour prior to sessions 2-5 of a 5-session group exposure-based CBT protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy</description>
        </group>
        <group group_id="B2">
          <title>Yohimbine Hydrochloride</title>
          <description>Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.70" spread="12.08"/>
                    <measurement group_id="B2" value="35.50" spread="14.02"/>
                    <measurement group_id="B3" value="36.13" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Liebowitz Social Anxiety Scale (LSAS)</title>
        <description>The Liebowitz Social Anxiety Scale (LSAS) is a self-report measure of social anxiety symptom severity. Scores range from 0 to 144, with higher scores indicating more social anxiety symptoms severity (i.e., a worse outcome).</description>
        <time_frame>LSAS means at 1 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy</description>
          </group>
          <group group_id="O2">
            <title>Yohimbine Hydrochloride</title>
            <description>Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Liebowitz Social Anxiety Scale (LSAS)</title>
          <description>The Liebowitz Social Anxiety Scale (LSAS) is a self-report measure of social anxiety symptom severity. Scores range from 0 to 144, with higher scores indicating more social anxiety symptoms severity (i.e., a worse outcome).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="22.0"/>
                    <measurement group_id="O2" value="33.3" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.015</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>10.46</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Phobic Disorders Severity and Change Form</title>
        <description>Social Phobic Disorders Severity and Change (SPDSC) Form is a version of the Clinical Global Improvement-Severity scale adapted specifically for clinician ratings of social anxiety disorder symptom severity. The scale ranges from 0 to 5, with higher scores indicating more social anxiety symptoms severity (i.e., worse outcomes). We examined the change in SPDSC scores from baseline to a 1 month follow-up.</description>
        <time_frame>CGI change scores from baseline to 1 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy</description>
          </group>
          <group group_id="O2">
            <title>Yohimbine Hydrochloride</title>
            <description>Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Social Phobic Disorders Severity and Change Form</title>
          <description>Social Phobic Disorders Severity and Change (SPDSC) Form is a version of the Clinical Global Improvement-Severity scale adapted specifically for clinician ratings of social anxiety disorder symptom severity. The scale ranges from 0 to 5, with higher scores indicating more social anxiety symptoms severity (i.e., worse outcomes). We examined the change in SPDSC scores from baseline to a 1 month follow-up.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.9"/>
                    <measurement group_id="O2" value="2.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.575</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>.03</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy</description>
        </group>
        <group group_id="E2">
          <title>Yohimbine Hydrochloride</title>
          <description>Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sweaty palms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Decrease in sexual arousal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Jittery/Jumpy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Light-headedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alertness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dazed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Open sinuses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hot flash/chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pressure around the eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jasper Smits, Ph.D.</name_or_title>
      <organization>Southern Methodist University</organization>
      <phone>214-768-4310</phone>
      <email>jsmits@smu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

